Latest news with #OTTAVA
Yahoo
18-04-2025
- Health
- Yahoo
Weekly Recap: 15 Health Press Releases You Need to See
A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including the first use of Johnson & Johnson's robotic surgical system and a staggering global statistic on pediatric antimicrobial resistance. NEW YORK, April 18, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Johnson & Johnson MedTech Announces Completion of First Cases with OTTAVA™ Robotic Surgical SystemOTTAVA is designed as a multi-specialty soft-tissue surgery robot, supporting a broad range of procedures across patient anatomy and surgical specialties, including the most complex surgeries that require a multi-quadrant approach. Novo Nordisk warns consumers about counterfeit Ozempic® (semaglutide) injection 1 mg in the USNovo Nordisk has become aware of several hundred units of Ozempic® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the US. The US Food and Drug Administration (FDA) has also updated its website with information about these counterfeit versions of Ozempic. IMDELLTRA® Demonstrated Superior Overall Survival in Small Cell Lung CancerIMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) compared to local standard-of-care (SOC) chemotherapy. Jay Bradner, M.D., executive vice president, Research and Development, at Amgen, commented on the "overwhelming clinical benefit" stating the results "affirm IMDELLTRA as standard of care." The Elizabeth Taylor AIDS Foundation Issues Emergency Grant Cycle to Address Forthcoming Gap FundingProviding financial resources to organizations in need, the initiative will be aimed at ensuring that critical, wrap-around health services for HIV treatment & prevention and programs focused on Transgender communities can continue to operate into the near future. Over 3 million children died from AMR-related infections in 2022, major study showsThe study data found that in 2022 alone, more than 752,000 children in Southeast Asia and 659,000 children in Africa died of antimicrobial resistance (AMR)-related infections. Globally, of the more than 3 million children's deaths, 2 million were associated with the use of Watch and Reserve antibiotics. SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNAPreliminary data showed Novavax's non-mRNA JN.1 COVID-19 vaccine induced lower frequency and severity of short-term side effects and impact on daily life compared with Pfizer-BioNTech mRNA vaccine. Crunch Fitness Announces Strategic Investment from Leonard Green & PartnersUnder the terms of the agreement, LGP will acquire a majority interest in Crunch Fitness from TPG Growth, the middle market and growth equity platform of global alternative asset management firm TPG, and Crunch's minority shareholders. Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial"As a convenient once-daily pill, orforglipron may provide a new option and, if approved, could be readily manufactured and launched at scale for use by people around the world," said David A. Ricks, Lilly chair and CEO. Hyundai Hope on Wheels Commemorates 27th Anniversary with $27 Million Donation to Pediatric Cancer Research"Hyundai Hope on Wheels has been a driving force in pediatric cancer research for nearly three decades, and we are proud to expand its reach beyond the U.S. to support children throughout North America," said Randy Parker, president and CEO, Hyundai Motor North America. Norgine strengthens rare disease portfolio with acquisition of TheraviaThe acquisition of Theravia from Mérieux Equity Partners represents a meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines. New Docuseries People Worth Caring About Shines a Light on Ohio's Long-Term Care WorkersLong-term care workers play a critical role in the well-being of hundreds of thousands of Ohio residents, yet their stories often go untold. People Worth Caring About seeks to change that by showcasing the personal and professional journeys of these caregivers, illuminating the challenges they face and the deep fulfillment they find in their work. Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovationThe collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients. Recently Discovered Immune Cell Type Is Key to Understanding Food AllergiesA new study led by researchers at NYU Langone Health has revealed that a special group of cells in the intestines tamp down the immune responses caused by exposure to food proteins. Called "tolerogenic dendritic cells," these cells enable food to pass through the body without triggering an immune reaction, unless they malfunction to cause allergies. Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer DiagnosisOptellum's Virtual Nodule Clinic (VNC) is the first FDA-cleared AI-powered decision support tool for early-stage lung cancer, reimbursed by CMS and implemented by leading health systems. New Research to Examine the Impact of Service Dogs On Post Traumatic Growth in Veterans with PTSD"Most research on PTSD has focused on the negative impacts of trauma exposure, but more recently, there has been growing interest in the potential for positive shifts after traumatic experiences," said Dr. Kevin Morris, the Principal Investigator of this research project. "We hypothesize that pairing veterans with PTSD and psychiatric service dogs will help promote this positive growth, which may include feelings of hope, agency, and a sense of purpose or meaning in life." For more news like this, check out all of the latest health-related releases from PR Newswire. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at View original content to download multimedia: SOURCE PR Newswire Sign in to access your portfolio
Yahoo
14-04-2025
- Business
- Yahoo
Johnson & Johnson MedTech Announces Completion of First Cases with OTTAVA™ Robotic Surgical System
First use in gastric bypass at Memorial Hermann-Texas Medical Center Trial will support submission for multiple procedures NEW BRUNSWICK, N.J., April 14, 2025 /PRNewswire/ -- Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, today announced completion of the first cases in the clinical trial for the OTTAVA™ Robotic Surgical System. The cases mark the first clinical experience with the OTTAVA System. Dr. Erik Wilson*, Chief of Minimally Invasive and Elective General Surgery UT Health Houston and the lead investigator for the clinical study, performed Roux-en-Y gastric bypass surgery using the OTTAVA Robotic Surgical System at Memorial Hermann-Texas Medical Center. "Surgical robotics is at the forefront of innovation in minimally invasive surgery," Dr. Wilson said. "I am proud to have performed the first clinical study cases with OTTAVA and potentially help advance the standard in surgical robotics." OTTAVA is designed as a multi-specialty soft-tissue surgery robot, supporting a broad range of procedures across patient anatomy and surgical specialties, including the most complex surgeries that require a multi-quadrant approach. Data from this investigation aims to support the system's ability to perform a variety of procedures. Upon completion of the study, the company plans to submit the OTTAVA system for De Novo authorization in the United States, targeting an indication covering multiple procedures in general surgery within the upper abdomen, such as gastric bypass, gastric sleeve, small bowel resection and hiatal hernia repair. "We are proud to reach this important milestone in our robotic surgery program," said Hani Abouhalka, Company Group Chairman, Surgery, Johnson & Johnson MedTech. "OTTAVA is a key innovation in our portfolio of advanced surgical technologies – all of which are designed to transform the surgical experiences across all surgery. Our people work side-by-side with surgical teams in ORs around the world every day to raise the standard of care for patients and deliver what's next in surgery." Johnson & Johnson MedTech's OTTAVA system received investigational device exemption (IDE) approval from the U.S. FDA in late 2024. The system is designed to advance clinical innovation in general surgery, a stronghold for Johnson & Johnson MedTech's broader surgery business. OTTAVA is designed to address unmet needs that persist in robotic surgery today and support complex procedures. The system's unique unified architecture, surgical instrumentation powered by Ethicon expertise, and future connection to the Polyphonic™ digital ecosystem are designed to meet the needs of each patient's care and each surgeon's clinical approach. "As a company operating at the intersection of biology and technology, clinical evidence generation is the core of our innovation programs to advance surgical technology for patients," said Peter Schulam M.D., PhD, Chief Scientific Officer, Johnson & Johnson MedTech. "Through this clinical study, we are proud to be partnering with surgeons to gather evidence and support the ongoing pursuit of scientific study for the advancement of robotic-assisted minimally invasive surgery." The OTTAVA robotic system is under development and is not authorized to be marketed or sold in any market. For more information, visit: Surgical Solutions from Johnson & Johnson MedTech Across Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. For over 100 years, we have helped advance surgical care through our innovative portfolio across wound closure, adjunctive hemostats, surgical stapling and instruments, robotics and digital solutions. Together, with clinicians and healthcare experts around the world we are progressing what's next in surgery to better solve patient needs in metabolic and cardiovascular disease, cancer, and aesthetics and reconstruction. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopedics, surgery and vision solutions at Follow us at @JNJMedTech and on LinkedIn. Auris Health, Inc. is part of Johnson & Johnson MedTech. *Dr. Wilson is a paid consultant for Johnson & Johnson MedTech. NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the OTTAVA™ Robotic Surgical System. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. © Johnson & Johnson and its affiliates 2025. US_SRG_RADS_399335 Media contact:Lindsey Diaz-MacInnisldiazmac@ Investor Relations:Tracy MenkowskiInvestor-relations@ View original content to download multimedia: SOURCE Johnson & Johnson MedTech
Associated Press
14-04-2025
- Business
- Associated Press
Johnson & Johnson MedTech Announces Completion of First Cases with OTTAVA™ Robotic Surgical System
First use in gastric bypass at Memorial Hermann-Texas Medical Center Trial will support submission for multiple procedures NEW BRUNSWICK, N.J., April 14, 2025 /PRNewswire/ -- Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, today announced completion of the first cases in the clinical trial for the OTTAVA™ Robotic Surgical System. The cases mark the first clinical experience with the OTTAVA System. Dr. Erik Wilson*, Chief of Minimally Invasive and Elective General Surgery UT Health Houston and the lead investigator for the clinical study, performed Roux-en-Y gastric bypass surgery using the OTTAVA Robotic Surgical System at Memorial Hermann-Texas Medical Center. 'Surgical robotics is at the forefront of innovation in minimally invasive surgery,' Dr. Wilson said. 'I am proud to have performed the first clinical study cases with OTTAVA and potentially help advance the standard in surgical robotics.' OTTAVA is designed as a multi-specialty soft-tissue surgery robot, supporting a broad range of procedures across patient anatomy and surgical specialties, including the most complex surgeries that require a multi-quadrant approach. Data from this investigation aims to support the system's ability to perform a variety of procedures. Upon completion of the study, the company plans to submit the OTTAVA system for De Novo authorization in the United States, targeting an indication covering multiple procedures in general surgery within the upper abdomen, such as gastric bypass, gastric sleeve, small bowel resection and hiatal hernia repair. 'We are proud to reach this important milestone in our robotic surgery program,' said Hani Abouhalka, Company Group Chairman, Surgery, Johnson & Johnson MedTech. 'OTTAVA is a key innovation in our portfolio of advanced surgical technologies – all of which are designed to transform the surgical experiences across all surgery. Our people work side-by-side with surgical teams in ORs around the world every day to raise the standard of care for patients and deliver what's next in surgery.' Johnson & Johnson MedTech's OTTAVA system received investigational device exemption (IDE) approval from the U.S. FDA in late 2024. The system is designed to advance clinical innovation in general surgery, a stronghold for Johnson & Johnson MedTech's broader surgery business. OTTAVA is designed to address unmet needs that persist in robotic surgery today and support complex procedures. The system's unique unified architecture, surgical instrumentation powered by Ethicon expertise, and future connection to the Polyphonic™ digital ecosystem are designed to meet the needs of each patient's care and each surgeon's clinical approach. 'As a company operating at the intersection of biology and technology, clinical evidence generation is the core of our innovation programs to advance surgical technology for patients,' said Peter Schulam M.D., PhD, Chief Scientific Officer, Johnson & Johnson MedTech. 'Through this clinical study, we are proud to be partnering with surgeons to gather evidence and support the ongoing pursuit of scientific study for the advancement of robotic-assisted minimally invasive surgery.' The OTTAVA robotic system is under development and is not authorized to be marketed or sold in any market. For more information, visit: Surgical Solutions from Johnson & Johnson MedTech Across Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. For over 100 years, we have helped advance surgical care through our innovative portfolio across wound closure, adjunctive hemostats, surgical stapling and instruments, robotics and digital solutions. Together, with clinicians and healthcare experts around the world we are progressing what's next in surgery to better solve patient needs in metabolic and cardiovascular disease, cancer, and aesthetics and reconstruction. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopedics, surgery and vision solutions at Follow us at @JNJMedTech and on LinkedIn. Auris Health, Inc. is part of Johnson & Johnson MedTech. *Dr. Wilson is a paid consultant for Johnson & Johnson MedTech. NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS: This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding the OTTAVA™ Robotic Surgical System. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. © Johnson & Johnson and its affiliates 2025. US_SRG_RADS_399335 Media contact: Lindsey Diaz-MacInnis [email protected] Investor Relations: Tracy Menkowski [email protected] View original content to download multimedia: SOURCE Johnson & Johnson MedTech
